OneSource Q4 Revenue Up 47% with 5x EBITDA Growth

OneSource reported Q4FY26 revenue of ₹4,282 million, up 47% QoQ, driven by semaglutide launches in India and growth across all service offerings.
EBITDA surged over 5x quarter-on-quarter to ₹919 million with margins expanding 1550bps due to operating leverage on higher CSA revenues.
The company reaffirmed its FY28 guidance of ~$400 million organic revenue with ~40% EBITDA margin, supported by GLP-1 scaling and biologics expansion.
Operational highlights include first generic semaglutide approvals in G7 countries, 50+ multi-project customers, and receiving USFDA EIR for its flagship site.